Evidence map›Paper›PMID 36056982›Full record

ArticleMolecular neurobiology2022

Neuroprotective Effect of Sonic Hedgehog Mediated PI3K/AKT Pathway in Amyotrophic Lateral Sclerosis Model Mice.

Yan Qi, Chen Yang, Hui Zhao, Zhanjin Deng, Jin Xu, Weijing Liang, Zhitang Sun, John Dirk Vestergaard Nieland

Open access · hybridAbstract read
In one paragraph

Article in Molecular neurobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. The Therapeutic Potential of Purmorphamine Across Disease Models.Journal of cellular and molecular medicine · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Yan QiDepartment of Neurology, Second Hospital of Shanxi Medical University, Shanxi, China.
Chen YangDepartment of Neurology, Second Hospital of Shanxi Medical University, Shanxi, China.
Hui ZhaoShanxi Medical University, Shanxi, China.
Zhanjin DengDepartment of Neurology, Second Hospital of Shanxi Medical University, Shanxi, China.
Jin XuShanxi Medical University, Shanxi, China.
Weijing LiangShanxi Medical University, Shanxi, China.
Zhitang SunDepartment of Neurology, Second Hospital of Shanxi Medical University, Shanxi, China. 271430793@qq.com.ORCID http://orcid.org/0000-0002-1211-1301
John Dirk Vestergaard NielandDepartment of Health Science and Technology, Aalborg University, 9220, Aalborg, Denmark.
Shanxi Medical University · CNAalborg University · DK

Funding

Department of Education of Shanxi Province 2019L0434ShanXi Science and Technology Department 201901D211500
6 · The paper itself

Abstract

The Sonic Hedgehog (SHH) signaling pathway is related to the progression of various tumors and nervous system diseases. Still, its specific role in neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), remains studied. This research investigates the role of SHH and PI3K/AKT signaling pathway proteins on ALS development in a SOD1-G93A transgenic mouse model. After injection of SHH and PI3K/AKT signaling pathway inhibitors or agonists in hSOD1-G93A (9 weeks of age) transgenic mice, we studied skeletal muscle pathology using immunohistochemical staining and Western blot methods. In addition, recorded data on rotation time, weight, and survival were analyzed for these mice. Our study showed that the expression of SHH, Gli-1 and p-AKT in ALS mice decreased with the progression of the disease. The expression of p-AKT changed together with Gli-1 while injecting PI3K/AKT signaling pathway inhibitor or agonist; SHH and Gli-1 protein expression remained unchanged; p-AKT protein expression significantly decreased while injecting PI3K/AKT signaling pathway inhibitor. These results indicate that SHH has a regulatory effect on PI3K/AKT signaling pathway. In behavioral experiments, we found that the survival time of hSOD1-G93A mice was prolonged by injection of SHH agonist while shortened by injection of SHH inhibitor. In conclusion, we confirmed that the SHH pathway played a neuroprotective role in ALS by mediating PI3K/AKT signaling pathway.

Indexed as

Amyotrophic Lateral SclerosisNeuroprotective AgentsAnimalsDisease Models, AnimalHedgehog ProteinsMiceMice, TransgenicPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins c-aktSuperoxide DismutaseSuperoxide Dismutase-1Hedgehog ProteinsNeuroprotective AgentsPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins c-aktSuperoxide DismutaseSuperoxide Dismutase-1ALSGli-1PI3K/AKT signaling pathwaySHHSOD1-G93A

Identifiers

PMID36056982
PMCPMC9525365
OpenAlexW4294414971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.